Rinat Neuroscience Corporation

Ngm Biopharmaceuticals, Inc.

Genentech, Inc.

F. Hoffmann-la Roche Ag

Wenwu Zhai

Yan Wang

Zhonghao Liu

Yiyuan Yin

Chia-Yang Lin

Li-Fen Lee

Philip E Hass

Menno Van Lookeren Campagne

Gerald R Nakamura

Meredith C Hazen

Nancy Chiang

Dhaya Seshasayee

Jack Bevers, Iii

Yi-Chun Hsiao

Rajita Khosla

Hongkang Xi

Jie Tang

Xunshan Ding

Dana Yen Mei Duey

Jared Martin Higbee

Chun Chu

David L Shelton

Pavel Strop

Javier Fernando Chaparro Riggers

Davide Foletti

Jacob Eli Gunn Glanville

Lee Mary Beth Shaughnessy

Meredith Hazen

Jack Iii Bevers

The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.

C3-binding agents and methods of use thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof

Anti-C3 antibodies

ANGPTL8-binding agents and methods of use thereof

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

Antagonist anti-IL-7 receptor antibodies and methods

Method of treating type 1 diabetes with antagonist IL-7 receptor antibodies

The present invention provides antagonizing antibodies that bind toalpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.

[object Object]

Nucleic acid encoding IL-7 receptor alpha antibody

Anti-IL-7 receptor antibodies

Growing community of inventors

Redwood City, CA, United States of America

Wenwu Zhai